Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049829 · ClinicalTrials.gov registry record · Phase 3
HORIZON-PFT: Pivotal Fracture Trial
A Phase 3 study of Osteoporosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 7,700
- Enrollment target
- 20
- Study locations
NCT00049829 is a Phase 3 study of Osteoporosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 7,700 participants, above the 1,454-participant average among 84 other Osteoporosis trials with a reported enrollment target (430% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00049829, a Phase 3 study of Osteoporosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 7,700 participants
- Enrollment target
- 20
- Study locations
Study Summary
HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.
Conditions Studied
Interventions
- DRUG Zoledronic Acid
Study Locations (20)
California
- Osteoporosis Medical Center - Beverly Hills
- Orthopaedic Hospital - Los Angeles
- The Foundation for Osteoporosis Research and Education - Oakland
- University of California Davis- Gen Med Research - Sacramento
- Osteoporosis Prevention Center - San Diego
- Radiant Research- San Diego - San Diego
- Diablo Clinical Research, Inc - Walnut Creek
Florida
- CRA Research - Fort Lauderdale
- Anchor Research Center - Naples
- Sarasota Arthritis Center - Sarasota
- Radiant - Stuart
- Comprehensive Clinical Trials, LLC - West Palm Beach
Arizona
- Arizona Arthritis Research - Paradise Valley
- Southern Arizona VA - Tucson
Colorado
- Colorado Center for Bone Research - Lakewood
- Longmont Medical Research Network - Longmont
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- University of Arkansas for Medical Science - Little Rock
Connecticut
- Northeast Clinical Research - Hamden
Delaware
- Health Core - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,700 participants |
| Start Date | 2002-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049829
The ClinicalTrials.gov registry entry for NCT00049829 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 7,700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,454-participant average among 84 other Osteoporosis trials with a reported enrollment target (430% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which Zoledronic Acid is the first listed.
NCT00049829 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT00049829 about?
NCT00049829 is a clinical study titled "HORIZON-PFT: Pivotal Fracture Trial". HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledr...
What is the current status of trial NCT00049829?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 7,700 participants. The study started on 2002-01.
What conditions does trial NCT00049829 study?
This clinical trial studies the following conditions: Osteoporosis.
What interventions are being tested in trial NCT00049829?
The interventions under investigation include: Zoledronic Acid (DRUG).
Who is sponsoring clinical trial NCT00049829?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00049829 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EffCaMgCit to Prevent Mineral Metabolism and Renal Complications of Chronic PPI Therapy
RECRUITING · Phase 3
-
Effect of Vitamin K on Age-Related Bone Loss and Vascular Calcification
COMPLETED · Phase 3
-
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
COMPLETED · Phase 3
-
Secondary Prevention of Osteoporosis
COMPLETED · Phase 3
-
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
COMPLETED · Phase 3
-
Toremifene Citrate for Prevention of Bone Fractures in Men With Prostate Cancer on Androgen Deprivation Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.